Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...
Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Wolfe Research initiated coverage of Bristol Myers (BMY) with a Peer Perform rating. The firm said there maybe a comeback story with Bristol, ...
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...